Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ECE1 | P42892 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22804047 | 1.00 | MME (0.44) | MMEECE1KMT2APNMTTGM2 | |
| SCHEMBL16695025 | 1.00 | MME (0.44) | MMEECE1KMT2APNMTTGM2 | |
| SCHEMBL2551608 | 0.92 | FOLH1 (0.45) | MMEECE1PNMTTGM2ACE | |
| SCHEMBL2551604 | 0.92 | FOLH1 (0.45) | MMEECE1PNMTTGM2ACE | |
| SCHEMBL21596245 | 0.91 | PNMT (0.43) | MMEECE1KMT2APNMTTGM2 | |
| SCHEMBL22804115 | 0.91 | PNMT (0.43) | MMEECE1KMT2APNMTTGM2 | |
| SCHEMBL9653586 | 0.91 | PNMT (0.43) | MMEECE1KMT2APNMTTGM2 | |
| SCHEMBL30940317 | 0.89 | SIRT2 (0.43) | PNMTTGM2ACE | |
| SCHEMBL21315797 | 0.89 | ACE (0.47) | ECE1PNMTTGM2ACE | |
| SCHEMBL28019287 | 0.89 | ACE (0.47) | ECE1PNMTTGM2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| EP-4659764-A1 | LINKER DRUG, AND PREPARATION METHOD AND USE OF ANTIBODY-DRUG CONJUGATE THEREOF | Lepu Biopharma Co., Ltd. (CN) | 2025-12-10 | — | — | EP | disclosed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | disclosed |
| EP-1613420-B1 | METHOD FOR SELECTIVELY BINDING A SUBSTRATE TO SORBENTS BY WAY OF AT LEAST BIVALENT BONDS | INSTRACTION GMBH (DE) | 2015-05-13 | — | — | EP | disclosed |
| US-20110257028-A1 | Method for selectively binding a substrate to sorbents by way of at least bivalent bonds | INSTRACTION GMBH (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20060292569-A1 | Method for selectively binding a substrate to sorbents by way of at least bivalent bonds | INSTRACTION GMBH (DE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257028-A1 | Method for selectively binding a substrate to sorbents by way of at least bivalent bonds | SPR, ABCG2, SHBG | MME 583/4885ECE1 1995/4885KMT2A 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.